Clinical Trial Update: Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases [NA]

View source ↗

Summary

Clinical trial update for Radium 223 in castration-resistant prostate cancer with bone metastases; study completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Radium-223 (radium-223 dichloride)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Prostate Cancer | NA | Status: COMPLETED | Results posted: 2022-02-17